Source: National Institute for Health Research Health Technology Assessment programme.
Area: News
Infusion of verteporfin followed by infrared laser exposure is called (verteporfin photodynamic therapy -VPDT), and is used to treat neovascular age-related macular degeneration (nAMD). The VPDT cohort study advised clinicians to follow patients every 3 months during treatment or active observation, retreating based on criteria used in the previous commercial 'TAP' (Treatment of Age-related macular degeneration with Photodynamic therapy) trials of VPDT.
The VPDT study aimed to answer five questions:
1. Is VPDT in the NHS provided as in randomised trials?
2. Is 'outcome' the same in the NHS as in randomised trials?
3. Is 'outcome' the same for patients ineligible for randomised trials?
4. Is VPDT safe when provided in the NHS?
5. How effective and cost-effective is VPDT?
The main outcome measure was the logarithm of the minimum angle of resolution monocular best-corrected distance visual acuity (BCVA). ...
Uncategorized